Taking aim at a dynamic target: Noscapinoids as microtubule-targeted cancer therapeutics

Pharmacological Reports

Volumn 67, Issue 1, 2015, Pages 56-62

  Lopus, Manu ^a   Naik, Pradeep Kumar ^b  

^a UM DAE CENTRE FOR EXCELLENCE IN BASIC SCIENCES   (India)

^b GURU GHASIDAS UNIVERSITY   (India)

Author keywords

Anticancer agents; Microtubule; Noscapine; Noscapinoids; Tubulin

Indexed keywords

ALPHA TUBULIN; AMINO NOSCAPINE; ANTINEOPLASTIC AGENT; AZIDO NOSCAPINE; BENZOFURANONE DERIVATIVE; BETA TUBULIN; BROMO NOSCAPINE; COLCHICINE; HALOGENATED NOSCAPINOID DERIVATIVE; NOSCAPINE DERIVATIVE; NOSCAPINOID DERIVATIVE; UNCLASSIFIED DRUG; NOSCAPINE; TUBULIN;

ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER REGRESSION; CELL CYCLE ARREST; CELL DEATH; CYTOTOXICITY; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SCREENING; DRUG STRUCTURE; FIBROBLAST; HUMAN; MICROTUBULE; MOLECULAR DYNAMICS; NON SMALL CELL LUNG CANCER; NONHUMAN; REVIEW; STRUCTURE ACTIVITY RELATION; TISSUE SPECIFICITY; ANIMAL; DRUG EFFECTS; METABOLISM; NEOPLASMS; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; HUMANS; MICROTUBULES; NEOPLASMS; NOSCAPINE; TUBULIN;

EID: 84908539510     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/j.pharep.2014.09.003     Document Type: Review

References (42)

1. Warolin C. Pierre-Jean Robiquet. Rev Hist Pharm (Paris) 1999; 47(321):97-110.
2. Mahmoudian M, Rahimi-Moghaddam P. The anti-cancer activity of noscapine: a review. Recent Pat Anticancer Drug Discov 2009; 4(1):92-7.
3. Singh H, Singh P, Kumari K., Chandra A, Dass SK, Chandra R. A review on noscapine, and its impact on heme metabolism. Curr Drug Metab 2013; 14(3): 351-60.
4. Fojo TA. In: Fojo TA, editor. The role of microtubules in cell biology, neurobiology, and oncology. London: Humana Press; 2008.
5. Yenjerla M, Lopus M, Wilson L Analysis of dynamic instability of steady-state microtubules in vitro by video-enhanced differential interference contrast microscopy with an appendix by Emin Oroudjev. Method Cell Biol 2010; 95: 189-206.
6. Katsetos CD, Dráber P. Tubulins as therapeutic targets in cancer: from bench to bedside. Curr Pharm Des 2012; 18(19):2778-92.
7. Dumontet C, Jordan MA Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov 2010; 9(10):790-803.
8. Lopus M, Oroudjev E, Wilson L., Wilhelm S, Widdison W, Chari R., et al. Maytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules. Mol Cancer Ther 2010; 9(10):2689-99.
9. Risinger AL, Riffle SM, Lopus M, Jordan M.A., Wilson L., Mooberry SL. The taccalonolides and paclitaxel cause distinct effects on microtubule dynamics and aster formation. Mol Cancer 2014; 13:41.
10. Lopus M, Manatschal C, Buey R.M., Bjelic S., Miller HP, Steinmetz MO, et al. Cooperative stabilization of microtubule dynamics by EB1 and CLIP-170 involves displacement of stably bound P(i) at microtubule ends. Biochemistry 2012; 51(14):3021-30.
11. Manna T, Thrower D, Miller H.P., Curmi P., Wilson L. Stathmin strongly increases the minus end catastrophe frequency and induces rapid treadmilling of bovine brain microtubules at steady state in vitro. J Biol Chem 2006; 281(4):2071-8.
12. Dave RH, Saengsawang W, Lopus M., Dave S, Wilson L, Rasenick MM A molecular and structural mechanism for G protein-mediated microtubule destabilization. J Biol Chem 2011; 286(6):4319-28.
13. Kamath K, Okouneva T, Larson G., Panda D, Wilson L, Jordan MA 2-Methox-yestradiol suppresses microtubule dynamics and arrests mitosis without depolymerizing microtubules. Mol Cancer Ther 2006; 5(9):2225-33.
14. Zhou J, Yao J, Joshi HC Attachment and tension in the spindle assembly checkpoint. J Cell Sci 2002; 115(18):3547-55.
15. Zhou J, Giannakakou P. Targeting microtubules for cancer chemotherapy. Curr Med Chem Anticancer Agents 2005; 5(1):65-71.
16. Newcomb EW, Lukyanov Y, Smirnova I, Schnee T, Zagzag D. Noscapine induces apoptosis in human glioma cells by an apoptosis-inducing factor-dependent pathway. Anticancer Drugs 2008; 19(6):553-63.
17. Aneja R, Ghaleb AM, Zhou J, Yang V.W., Joshi HC. p53 and p21 determine the sensitivity of noscapine-induced apoptosis in colon cancer cells. Cancer Res 2007; 67(8):3862-70.
18. Heidari N, Goliaei B, Moghaddam P.R., Rahbar-Roshandel N, Mahmoudian M. Apoptotic pathway induced by noscapine in human myelogenous leukemic cells. Anticancer Drugs 2007; 18(10):1139-47.
19. Jackson T, Chougule MB, Ichite N, Patlolla R.R., Singh M. Antitumor activity of noscapine in human non-small cell lung cancer xenograft model. Cancer Chemother Pharmacol 2008; 63(1):117-26.
20. Aneja R, Dhiman N, Idnani J., Awasthi A, Arora SK, Chandra R, et al Preclinical pharmacokinetics and bioavailability of noscapine, a tubulin-binding anticancer agent. Cancer Chemother Pharmacol 2007; 60(6):831-9.
21. Ke Y, Ye K, Grossniklaus H.E., Archer DR, Joshi HC, Kapp JA. Noscapine inhibits tumor growth with little toxicity to normal tissues or inhibition of immune responses. Cancer Immunol Immunother 2000; 49(4-5):217-25.
22. Ye K, Ke Y, Keshava N., Shanks J, Kapp JA, Tekmal R.R., et al. Opium alkaloid noscapine isan antitumor agent that arrests metaphase and induces apoptosis in dividing cells. Proc Natl Acad Sci U S A 1998; 95(4):1601-6.
23. Zhou J, Panda D, Landen J.W., Wilson L., Joshi HC. Minor alteration of microtu-bule dynamics causes lossoftension across kinetochore pairs and activates the spindle checkpoint. J Biol Chem 2002; 277(19):17200-08.
24. Aneja R, Vangapandu SN, Lopus M, Chandra R, Panda D, et al. Development of a novel nitro-derivative of noscapine for the potential treatment of drug-resistant ovarian cancer and Tcell lymphoma. Mol Pharmacol 2006; 69(6):1801-9.
25. Santoshi S, Naik PK, Joshi HC Rational design of novel anti-microtubule agent (9-azido-noscapine) from quantitative structure activity relationship (QSAR) evaluation of noscapinoids. J Biomol Screen 2011; 16(9):1047-58.
26. Naik PK, Chatterji BP, Vangapandu S.N., Aneja R., Chandra R, Kanteveri S, et al Rational design, synthesis and biological evaluations of amino-noscapine: a high affinity tubulin-binding noscapinoid. J Comput Aided Mol Des 2011; 25(5):443-54.
27. Aneja R, Vangapandu SN, Lopus M, Viswesarappa V.G., Dhiman N., Verma A, et al. Synthesis of microtubule-interfering halogenated noscapine analogues that perturb mitosis incancer cells followed by cell death. Biochem Pharmacol 2006; 72(4):415-26.
28. Aneja R, Vangapandu SN, Joshi HC Synthesis and biological evaluation of a cyclic ether fluorinated noscapine analog. Biorg Med Chem 2006; 14: 8352-8.
29. Mishra RC, Karna P, Gundala S.R., Pannu V., Stanton RA, Gupta KK, et al. Benzofuranone ring substituted noscapine analogs: synthesis and biological evaluation. Biochem Pharmacol 2011; 82(8):110-21.
30. Manchukonda NK, Naik PK, Santoshi S, Lopus M., Joseph S, Sridhar B, et al Rational design, synthesis, and biological evaluation of third generation α-noscapine analogues as potent tubulin binding anti-cancer agents. PLOS ONE 2013; 8:e77970.
31. Zhou J, Gupta K, Aggarwal S., Aneja R, Chandra R, Panda D., et al. Brominated derivatives of noscapine are potent microtubule-interfering agents that perturb mitosis and inhibit cell proliferation. Mol Pharmacol 2003; 63(4):799-807.
32. Aneja R, Zhou J, Vangapandu SN, Zhou B, Chandra R, Joshi HC. Drug-resistant T-lymphoid tumors undergo apoptosis selectively in response to an antimicro-tubule agent, EM011. Blood 2006; 107(6):2486-92.
33. Zhou J, Liu M, Aneja R, Chandra R, Joshi HC. Enhancement ofpaclitaxel-induced microtubule stabilization, mitotic arrest, and apoptosis by the microtubule-targeting agent EM012. Biochem Pharmacol 2004; 68(12):2435-41.
34. Zhou J, Liu M, Luthra R, Jones J, Aneja R, Chandra R, et al. EM012, a microtubule-interfering agent, inhibits the progression of multidrug-resistant human ovarian cancer both in cultured cells and in athymic nude mice. Cancer Chemother Pharmacol 2005; 55(5):461-5.
35. A study of noscapine HCl (CB3304) in patients with relapsed or refractory multiple myeloma (ID: NCT00912899), www.clinicaltrials.gov.
36. Lopus M. Antibody-DM1 conjugates as cancer therapeutics. Cancer Lett 2011; 307(2):113-8.
37. Oroudjev E, Lopus M, Wilson L., Audette C, Provenzano C, Erickson H., et al. Maytansinoid-antibody conjugates induce mitotic arrest by suppressing mi-crotubule dynamic instability. Mol Cancer Ther 2010; 9(10):2700-13.
38. Lopus M. Mechanism of mitotic arrest induced by dolast at in 15 involves loss of tension across kinetochore pairs. Mol Cell Biochem 2013; 382(1-2):93-102.
39. Gianolio DA, Rouleau C, Bauta W.E., Lovett D., Cantrell Jr WR, Recio III A, et al. Targeting HER2-positive cancer with dolastatin 15 derivatives conjugated to trastuzumab, novel antibody-drug conjugates. Cancer Chemother Pharmacol 2012; 70(3):439-49.
40. Chandra R, Madan J, Singh P., Chandra A, Kumar P, Tomar V, et al. Implications of nanoscale based drug delivery systems in delivery and targeting tubulin binding agent, noscapine in cancer cells. Curr Drug Metab 2012; 13(10):1476-83.
41. Madan J, Gundala SR, Kasetti Y, Bharatam P.V., Aneja R, Katyal A, et al. Enhanced noscapine delivery using estrogen-receptor-targeted nanoparticles for breast cancer therapy. Anticancer Drugs 2014; 25(6):704-16. PMID: 24642711.
42. Sun X, Li D, Yang Y., Ren Y, Li J, Wang Z., et al. Microtubule-binding protein CLIP-170 is a mediator of paclitaxel sensitivity. J Pathol 2012; 226(4):666-73.